Lercanidipino Ratiopharm

Lercanidipine, the active ingredient in Lercanidipino Ratiopharm, is a calcium channel blocker presented as a tablet for oral use. It is prescribed to lower high blood pressure in adults with essential hypertension and is available in the European Union market, conforming to EU pharmaceutical standards.

GNH USA supplies Lercanidipino Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality compliance and reliable delivery across global markets.

Lercanidipine is used as an antihypertensive agent acting on the vascular smooth muscle to control blood pressure.

Essential hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. Isolated systolic hypertension: provides effective blood pressure control especially in elderly patients.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Tachycardia - Nausea

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Cardiac arrhythmia - Angioedema - Hepatic dysfunction - Allergic reactions (e.g., rash, urticaria)

Before prescribing Lercanidipine, consider the following precautions.

Renal impairment: adjust therapy and monitor renal function. Hepatic dysfunction: monitor liver enzymes and consider dose modification. Concomitant use with strong CYP3A4 inhibitors: avoid or reduce dose to prevent toxicity. Pregnancy and lactation: use only if clearly needed, as safety data are limited. Elderly patients: start with a low dose and monitor blood pressure closely. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Lercanidipine can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels leading to toxicity. - Grapefruit juice: can markedly raise drug concentration. - Other antihypertensives (e.g., ACE inhibitors, ARBs): risk of excessive hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Diuretics: may enhance hypotensive effect. - Beta‑blockers: additive blood pressure lowering.